Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
20 okt 2009 - 15:01
Statutaire naam
Crucell N.V.
Titel
Crucell Rabies Monoclonal Antibody Combination: Positive Results Philippines Phase II Study Presented at RITA Conference
Bericht
Leiden, The Netherlands (October 20, 2009) – Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that detailed results of the Phase II Philippines study of its rabies monoclonal antibody combination (CL 184) were presented at the XX Rabies in the Americas (RITA) Conference in Quebec, Canada. The presentation was given by Dr Beatriz P. Quiambao (MD), Chief Clinical Research Division and Head, Rabies Research Group, Research Institute for Tropical Medicine, Muntinlupa, Philippines and is available on Crucell’s website www.crucell.com.
In June 2009, Crucell announced the results of the Phase II Philippines study in healthy adolescents and children, which showed that the antibody combination was safe and well tolerated. Neutralizing activity levels in subjects given the antibody product were similar to those in subjects given human rabies immunoglobulin (HRIG), the current standard for inducing immediate, passive immunity. All study participants reached adequate immunity levels. This study in a paediatric population, performed at the Research Institute for Tropical Medicine under the leadership of Dr Quiambao, further broadens the potential patient population for Crucell's rabies monoclonal antibody combination.
Datum laatste update: 20 december 2025